Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib versus standard temozolomide chemoradiation for newly diagnosed MGMT-unmethylated glioblastoma
ACTRN12615000407594Phase 2Completed
- Sponsor
- The University of Sydney
- Start
- Nov 2015
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of veliparib and temozolomide in glioblastoma (GBM), sponsored by The University of Sydney. Primary endpoint: Progression-free survival rate at 6 months. Started Nov 2015; status: completed.
02
Drugs
veliparibtemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ACTRN12615000407594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000407594.